172 related articles for article (PubMed ID: 12114872)
21. Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker.
Chang WC; Hung YC; Kao CH; Yen RF; Shen YY; Lin CC
Neoplasma; 2002; 49(5):329-33. PubMed ID: 12458332
[TBL] [Abstract][Full Text] [Related]
22. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages.
Wu JT; Erickson AJ; Tsao KC; Wu TL; Sun CF
Ann Clin Lab Sci; 2000 Apr; 30(2):175-8. PubMed ID: 10807161
[TBL] [Abstract][Full Text] [Related]
23. A review of the efficacy of bone scanning in prostate and breast cancer.
O'Sullivan JM; Cook GJ
Q J Nucl Med; 2002 Jun; 46(2):152-9. PubMed ID: 12114879
[TBL] [Abstract][Full Text] [Related]
24. Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare.
Bast RC
Trans Am Clin Climatol Assoc; 2004; 115():233-47; discussion 247-8. PubMed ID: 17060970
[TBL] [Abstract][Full Text] [Related]
25. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
26. [The accuracy of CT and tumor markers in the detection of a recurrent ovarian carcinoma].
Wakabayashi Y; Ishida J; Kotake F; Hirose M; Kawana K; Abe K; Amino S; Negishi Y; Akiya K
Gan No Rinsho; 1989 Sep; 35(10):1127-31. PubMed ID: 2550684
[TBL] [Abstract][Full Text] [Related]
27. Positron emission tomography and bone metastases.
Fogelman I; Cook G; Israel O; Van der Wall H
Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
[TBL] [Abstract][Full Text] [Related]
28. Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer.
Yang Y; Pospisil P; Iyer LK; Adelstein SJ; Kassis AI
PLoS One; 2008; 3(11):e3661. PubMed ID: 18987750
[TBL] [Abstract][Full Text] [Related]
29. Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
Ogawa A; Yoshida A; Kanda T; Sugihara S; Suzuki T; Tamura J; Kobayashi I; Nakazato Y
J Med; 2000; 31(1-2):101-10. PubMed ID: 10998759
[TBL] [Abstract][Full Text] [Related]
30. Cell-free DNA: measurement in various carcinomas and establishment of normal reference range.
Wu TL; Zhang D; Chia JH; Tsao K-; Sun CF; Wu JT
Clin Chim Acta; 2002 Jul; 321(1-2):77-87. PubMed ID: 12031596
[TBL] [Abstract][Full Text] [Related]
31. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
[TBL] [Abstract][Full Text] [Related]
32. Designing steroid receptor-based radiotracers to image breast and prostate tumors.
Katzenellenbogen JA
J Nucl Med; 1995 Jun; 36(6 Suppl):8S-13S. PubMed ID: 7769466
[TBL] [Abstract][Full Text] [Related]
33. The value of 18F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening.
Shen YY; Su CT; Chen GJ; Chen YK; Liao AC; Tsai FS
Neoplasma; 2003; 50(3):217-21. PubMed ID: 12937856
[TBL] [Abstract][Full Text] [Related]
34. Mucins and Cytokeratins as Serum Tumor Markers in Breast Cancer.
Nicolini A; Ferrari P; Rossi G
Adv Exp Med Biol; 2015; 867():197-225. PubMed ID: 26530368
[TBL] [Abstract][Full Text] [Related]
35. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
Ulbright TM
Mod Pathol; 2005 Feb; 18 Suppl 2():S61-79. PubMed ID: 15761467
[TBL] [Abstract][Full Text] [Related]
36. [Metastases to the breast from non-mammary malignancies: a clinicopathologic study of 28 cases].
Zhou S; Yu B; Cheng Y; Xu X; Shui R; Bi R; Lu H; Tu X; Yang W
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):231-5. PubMed ID: 24915812
[TBL] [Abstract][Full Text] [Related]
37. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
[TBL] [Abstract][Full Text] [Related]
38. Nuclear medicine studies of the prostate, testes, and bladder.
Jana S; Blaufox MD
Semin Nucl Med; 2006 Jan; 36(1):51-72. PubMed ID: 16356796
[TBL] [Abstract][Full Text] [Related]
39. Levels of alpha 2 macroglobulin can predict bone metastases in prostate cancer.
Kanoh Y; Ohtani N; Mashiko T; Ohtani S; Nishikawa T; Egawa S; Baba S; Ohtani H
Anticancer Res; 2001; 21(1B):551-6. PubMed ID: 11299802
[TBL] [Abstract][Full Text] [Related]
40. Pathways to personalized medicine for breast and prostate cancers: emerging diagnostic methods and prognostic biomarkers.
Watson AP; Egland KA
S D Med; 2010 Jul; 63(7):247-53. PubMed ID: 20666024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
